162 related articles for article (PubMed ID: 30515541)
1. Next-generation sequencing with a 54-gene panel identified unique mutational profile and prognostic markers in Chinese patients with myelofibrosis.
Gill H; Ip HW; Yim R; Tang WF; Pang HH; Lee P; Leung GMK; Li J; Tang K; So JCC; Leung RYY; Li J; Panagioutou G; Lam CCK; Kwong YL
Ann Hematol; 2019 Apr; 98(4):869-879. PubMed ID: 30515541
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathologic features and prognostic indicators in Chinese patients with myelofibrosis.
Gill H; Leung AY; Chan CC; Lau JS; Chan C; Yip SF; Liu H; Kho B; Mak V; Lee HK; Lin SY; Lau CK; Kwong YL
Hematology; 2016 Jan; 21(1):10-8. PubMed ID: 26292161
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of RAS-pathway mutations in patients with myelofibrosis.
Santos FPS; Getta B; Masarova L; Famulare C; Schulman J; Datoguia TS; Puga RD; Alves Paiva RM; Arcila ME; Hamerschlak N; Kantarjian HM; Levine RL; Campregher PV; Rampal RK; Verstovsek S
Leukemia; 2020 Mar; 34(3):799-810. PubMed ID: 31628430
[TBL] [Abstract][Full Text] [Related]
4. The clinical and prognostic relevance of driver mutations in 203 Taiwanese patients with primary myelofibrosis.
Kuo MC; Lin TH; Sun CF; Lin TL; Wu JH; Wang PN; Huang YJ; Chang H; Huang TY; Shih LY
J Clin Pathol; 2018 Jun; 71(6):514-521. PubMed ID: 29203554
[TBL] [Abstract][Full Text] [Related]
5. Next-generation sequencing with a myeloid gene panel in core-binding factor AML showed KIT activation loop and TET2 mutations predictive of outcome.
Cher CY; Leung GM; Au CH; Chan TL; Ma ES; Sim JP; Gill H; Lie AK; Liang R; Wong KF; Siu LL; Tsui CS; So CC; Wong HW; Yip SF; Lee HK; Liu HS; Lau JS; Luk TH; Lau CK; Lin SY; Kwong YL; Leung AY
Blood Cancer J; 2016 Jul; 6(7):e442. PubMed ID: 27391574
[TBL] [Abstract][Full Text] [Related]
6. Concomitant and noncanonical JAK2 and MPL mutations in JAK2V617F- and MPLW515 L-positive myelofibrosis.
Schulze S; Stengel R; Jaekel N; Wang SY; Franke GN; Roskos M; Schneider M; Niederwieser D; Al-Ali HK
Genes Chromosomes Cancer; 2019 Nov; 58(11):747-755. PubMed ID: 31135094
[TBL] [Abstract][Full Text] [Related]
7. Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group.
Rotunno G; Pacilli A; Artusi V; Rumi E; Maffioli M; Delaini F; Brogi G; Fanelli T; Pancrazzi A; Pietra D; Bernardis I; Belotti C; Pieri L; Sant'Antonio E; Salmoiraghi S; Cilloni D; Rambaldi A; Passamonti F; Barbui T; Manfredini R; Cazzola M; Tagliafico E; Vannucchi AM; Guglielmelli P
Am J Hematol; 2016 Jul; 91(7):681-6. PubMed ID: 27037840
[TBL] [Abstract][Full Text] [Related]
8. Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib.
Patel KP; Newberry KJ; Luthra R; Jabbour E; Pierce S; Cortes J; Singh R; Mehrotra M; Routbort MJ; Luthra M; Manshouri T; Santos FP; Kantarjian H; Verstovsek S
Blood; 2015 Aug; 126(6):790-7. PubMed ID: 26124496
[TBL] [Abstract][Full Text] [Related]
9. The role of new technologies in myeloproliferative neoplasms: Application of next-generation sequencing in myelofibrosis.
Navrátilová J; Palová M; Szotkowski T; Hluší A; Katrincsáková B; Papajík T; Indrák K
Int J Lab Hematol; 2021 Oct; 43(5):1070-1077. PubMed ID: 33734589
[TBL] [Abstract][Full Text] [Related]
10. A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis.
Passamonti F; Rumi E; Caramella M; Elena C; Arcaini L; Boveri E; Del Curto C; Pietra D; Vanelli L; Bernasconi P; Pascutto C; Cazzola M; Morra E; Lazzarino M
Blood; 2008 Apr; 111(7):3383-7. PubMed ID: 18187660
[TBL] [Abstract][Full Text] [Related]
11. [Prognostic value of JAK2, MPL and CALR mutations in Chinese patients with primary myelofibrosis].
Xu ZF; Li B; Liu JQ; Li Y; Ai XF; Zhang PH; Qin TJ; Zhang Y; Wang JY; Xu JQ; Zhang HL; Fang LW; Pan LJ; Hu NB; Qu SQ; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2016 Jul; 37(7):576-80. PubMed ID: 27535857
[TBL] [Abstract][Full Text] [Related]
12. Clinical impacts of the mutational spectrum in Japanese patients with primary myelofibrosis.
Morishita S; Ochiai T; Misawa K; Osaga S; Inano T; Fukuda Y; Edahiro Y; Ohsaka A; Araki M; Komatsu N
Int J Hematol; 2021 Apr; 113(4):500-507. PubMed ID: 33389584
[TBL] [Abstract][Full Text] [Related]
13. Mutational profiling in myelofibrosis: implications for management.
Bose P; Verstovsek S
Int J Hematol; 2020 Feb; 111(2):192-199. PubMed ID: 31630335
[TBL] [Abstract][Full Text] [Related]
14. EZH2 mutational status predicts poor survival in myelofibrosis.
Guglielmelli P; Biamonte F; Score J; Hidalgo-Curtis C; Cervantes F; Maffioli M; Fanelli T; Ernst T; Winkelman N; Jones AV; Zoi K; Reiter A; Duncombe A; Villani L; Bosi A; Barosi G; Cross NC; Vannucchi AM
Blood; 2011 Nov; 118(19):5227-34. PubMed ID: 21921040
[TBL] [Abstract][Full Text] [Related]
15. [Genetic characteristics and prognostic values of RAS mutations in patients with myelofibrosis].
Wu JY; Li B; Jia YJ; Zhang PH; Xu ZF; Qin TJ; Qu SQ; Pan LJ; Liu JQ; Yan X; Zhang YD; Chen J; Gong JY; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2020 Dec; 41(12):989-995. PubMed ID: 33445845
[No Abstract] [Full Text] [Related]
16. CALR mutation screening in pediatric primary myelofibrosis.
An W; Wan Y; Guo Y; Chen X; Ren Y; Zhang J; Chang L; Wei W; Zhang P; Zhu X
Pediatr Blood Cancer; 2014 Dec; 61(12):2256-62. PubMed ID: 25176567
[TBL] [Abstract][Full Text] [Related]
17. Genomic characterization and prognostication applied to a Brazilian cohort of patients with myelofibrosis.
Nonino A; Campregher PV; de Souza Santos FP; Mazzeu JF; Pereira RW
Int J Hematol; 2020 Sep; 112(3):361-368. PubMed ID: 32535855
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of ASXL1 mutations in patients with primary myelofibrosis and its relationship with clinical features: a meta-analysis.
Wang Z; Liu W; Wang M; Li Y; Wang X; Yang E; Ming J; Quan R; Hu X
Ann Hematol; 2021 Feb; 100(2):465-479. PubMed ID: 33386934
[TBL] [Abstract][Full Text] [Related]
19. Highly variable mutational profile of ASXL1 in myelofibrosis.
Sorigué M; Ribera JM; García O; Cabezón M; Vélez P; Marcé S; Xicoy B; Fernández C; Buch J; Cortes M; Plensa E; Gallardo D; Boqué C; Feliu E; Zamora L
Eur J Haematol; 2016 Oct; 97(4):331-5. PubMed ID: 26714837
[TBL] [Abstract][Full Text] [Related]
20. Mutations and prognosis in primary myelofibrosis.
Vannucchi AM; Lasho TL; Guglielmelli P; Biamonte F; Pardanani A; Pereira A; Finke C; Score J; Gangat N; Mannarelli C; Ketterling RP; Rotunno G; Knudson RA; Susini MC; Laborde RR; Spolverini A; Pancrazzi A; Pieri L; Manfredini R; Tagliafico E; Zini R; Jones A; Zoi K; Reiter A; Duncombe A; Pietra D; Rumi E; Cervantes F; Barosi G; Cazzola M; Cross NC; Tefferi A
Leukemia; 2013 Sep; 27(9):1861-9. PubMed ID: 23619563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
